Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04049552 · ClinicalTrials.gov registry record · Early Phase 1
RAPA-Keloid Study of Keloid Regression
A Early Phase 1 study of Keloid, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04049552: Completed Early Phase 1 study of Keloid, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04049552 is a Early Phase 1 study of Keloid that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 4 participants, below the 2,144-participant average among 8 other Keloid trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04049552, a Early Phase 1 study of Keloid, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
1. To test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months) 2. To test safety of product and feasibility of conduct for future clinical trial
Primary Outcome
Measurement of surface area of keloid
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rapamycin 8% Ointment
Study Locations (1)
Texas
- Audie L Murphy Memorial Veterans Hospital - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2021-05-02 |
| Phase | Early Phase 1 |
What the finished NCT04049552 record still lists
NCT04049552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 2,144-participant average among 8 other Keloid trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Keloid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04049552 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04049552 about?
NCT04049552 is a clinical study titled "RAPA-Keloid Study of Keloid Regression". 1. To test whether topical rapamycin regresses established keloids in humans by measuring surface area and height changes in the scar over time (6 months) 2. To test safety of product and feasibility of conduct for future clinical trial
What is the current status of trial NCT04049552?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2020-01-24. Estimated completion is 2021-05-02.
What conditions does trial NCT04049552 study?
This clinical trial studies the following conditions: Keloid.
What interventions are being tested in trial NCT04049552?
The interventions under investigation include: Placebo (DRUG), Rapamycin 8% Ointment (DRUG).
Who is sponsoring clinical trial NCT04049552?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04049552 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04049552's enrollment target sits among peer trials
4 9th of 8 the lowest of 8 other Keloid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keloid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids
COMPLETED · Early Phase 1
-
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
RECRUITING · Phase 2
-
Radiotherapy for Keloids
RECRUITING · NA
-
Genetic Analysis of Keloids
RECRUITING
-
Web Based Investigation of Natural History of Keloid Disorder, an Online Survey
RECRUITING
-
Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI